Travere Therapeutics, Inc. TVTX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$37.1M+10.0% | —— | $25.71M+147% | -$12.76M+81.9% | -$41.23M+69.7% | ||
| $25.21M+96.9% | $18.14M+50.0% | $15.79M+40.5% | $14.02M+35.5% | $12.8M+29.6% | ||
| $16.15M+40.5% | $11.46M+24.4% | $11.26M+40.4% | $10.65M+7.4% | $11.49M+17.8% | ||
| $7.23M+0.3% | —— | $44.16M+5,940% | $4.28M+146% | $7.2M+366% | ||
| $742K+120% | -$1.18M-513% | -$194K-179% | $0-100% | -$3.66M-301% | ||
| -$11.81M-42.2% | —— | -$1.11M+62.2% | —— | -$8.31M+66.6% | ||
| -$20.9M-119% | $17.34M— | $19.7M— | $1.34M+102% | -$9.54M-144% | ||
| $6.38M+282% | $0— | $1.33M-56.4% | $5.11M— | $1.67M-38.7% | ||
| $1.94M+174% | -$589K-180% | -$10.64M— | $816K— | $709K-91.2% | ||
| $4K-99.7% | —— | $807K— | —— | $1.57M+531% | ||
| $0+100% | —— | —— | -$1.47M+30.9% | -$1.35M+11.4% | ||
| -$40.37M+4.3% | $60.68M+270% | —— | —— | -$42.19M+64.5% | ||
| $48.78M-8.2% | $82.42M+49.7% | $106.62M+96.3% | $81.4M-22.9% | $53.16M-52.3% | ||
| $22.18M+88.2% | $19.24M+99.5% | $15.05M+83.7% | $12.09M+1.5% | $11.78M+82.2% | ||
| $21.55M-47.8% | —— | $86.59M+87.7% | $4.85M-83.0% | $41.29M-60.6% | ||
| $4.73M+11.5% | -$8.8M-107% | $4.09M+616% | $463K— | $4.24M— | ||
| $4.2M+13.1% | —— | -$65.34M-142,141% | $1.48M+88.6% | $3.72M+808% | ||
| -$60K-111% | —— | $207K-54.3% | $1.95M+1,888% | $548K+287% | ||
| -$14.67M-536% | —— | $35.78M+769% | $13.26M+221% | $3.36M+123% | ||
| —— | $2.21M0.0% | $2.21M0.0% | $2.21M0.0% | $2.21M0.0% | ||
| -$20.9M-119% | $17.34M— | $19.7M— | $1.34M+102% | -$9.54M-144% | ||
| $6.38M+282% | $0— | $1.33M-56.4% | $5.11M— | $1.67M-38.7% | ||
| $4K-99.7% | —— | $807K— | —— | $1.57M+531% | ||
| $0-100% | $470K+1,075% | -$3K— | -$146K— | $83K— | ||
| $22.18M+88.2% | $19.24M+99.5% | $15.05M+83.7% | $12.09M+1.5% | $11.78M+82.2% | ||
| $48.78M-8.2% | $82.42M+49.7% | $106.62M+96.3% | $81.4M-22.9% | $53.16M-52.3% | ||
| —— | $3.57M-7.5% | $3.57M-7.5% | $3.57M-7.5% | $3.57M-7.5% | ||
| —— | $1.64M+2.9% | $1.64M+2.9% | $1.64M+2.9% | $1.64M+2.9% | ||
| $525K0.0% | $525K0.0% | $525K0.0% | $525K0.0% | $525K0.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Travere Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Travere Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.